Cite
HARVARD Citation
Chang, J. et al. (2022). Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer. Lung cancer. pp. 71-81. [Online].